95 related articles for article (PubMed ID: 10714550)
1. Pharmacologic effect of recombinant human IFN-alpha, continuously released from a matrix prepared from a polyglycerol ester of fatty acids, on 2',5'-oligoadenylate synthetase activity in murine liver.
Yamagata Y; Yuasa Y; Yamamoto K; Okamoto K; Igari Y; Iga K; Ogawa Y
J Interferon Cytokine Res; 2000 Feb; 20(2):153-60. PubMed ID: 10714550
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers.
Salmon P; Le Cotonnec JY; Galazka A; Abdul-Ahad A; Darragh A
J Interferon Cytokine Res; 1996 Oct; 16(10):759-64. PubMed ID: 8910759
[TBL] [Abstract][Full Text] [Related]
3. Induction of blood 2',5'-oligoadenylate synthetase activity in mice by gastric administration of ovine IFN-tau.
Nakajima A; Sokawa Y
J Interferon Cytokine Res; 2002 Mar; 22(3):397-402. PubMed ID: 12034048
[TBL] [Abstract][Full Text] [Related]
4. Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial.
De Leede LG; Humphries JE; Bechet AC; Van Hoogdalem EJ; Verrijk R; Spencer DG
J Interferon Cytokine Res; 2008 Feb; 28(2):113-22. PubMed ID: 18279106
[TBL] [Abstract][Full Text] [Related]
5. Induction of 2'-5' oligoadenylate synthetase during interferon treatment of chronic myelogenous leukemia.
Moritz T; Weissmann B; Grünewald B; Hust H; Kummer G; Niederle N
Mol Biother; 1992 Jun; 4(2):97-102. PubMed ID: 1381190
[TBL] [Abstract][Full Text] [Related]
6. Impaired antiviral response in human hepatoma cells.
Keskinen P; Nyqvist M; Sareneva T; Pirhonen J; Melén K; Julkunen I
Virology; 1999 Oct; 263(2):364-75. PubMed ID: 10544109
[TBL] [Abstract][Full Text] [Related]
7. Minimal dose of aerosolized interferon-alpha in human subjects: biological consequences and side-effects.
Giosuè S; Casarini M; Ameglio F; Alemanno L; Saltini C; Bisetti A
Eur Respir J; 1996 Jan; 9(1):42-6. PubMed ID: 8834332
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma.
Fierlbeck G; Ulmer A; Schreiner T; Stroebel W; Schiebel U; Brzoska J
J Interferon Cytokine Res; 1996 Oct; 16(10):777-81. PubMed ID: 8910762
[TBL] [Abstract][Full Text] [Related]
9. Lipidization of human interferon-alpha: a new approach toward improving the delivery of protein drugs.
Yuan L; Wang J; Shen WC
J Control Release; 2008 Jul; 129(1):11-7. PubMed ID: 18448186
[TBL] [Abstract][Full Text] [Related]
10. Bile acids modulate the interferon signalling pathway.
Podevin P; Rosmorduc O; Conti F; Calmus Y; Meier PJ; Poupon R
Hepatology; 1999 Jun; 29(6):1840-7. PubMed ID: 10347128
[TBL] [Abstract][Full Text] [Related]
11. Changes of serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C.
Solinas A; Cossu P; Poddighe P; Tocco A; Deplano A; Garrucciu G; Diana MS
Liver; 1993 Oct; 13(5):253-8. PubMed ID: 8259037
[TBL] [Abstract][Full Text] [Related]
12. Time course of interferon levels, antiviral state, 2',5'-oligoadenylate synthetase and side effects in healthy men.
Barouki FM; Witter FR; Griffin DE; Nadler PI; Woods A; Wood DL; Lietman PS
J Interferon Res; 1987 Feb; 7(1):29-39. PubMed ID: 3035034
[TBL] [Abstract][Full Text] [Related]
13. Biological activities of a human amniotic membrane interferon.
Franco GR; de Carvalho AF; Kroon EG; Lovagie S; Werenne J; Golgher RR; Ferreira PC; Bonjardim CA
Placenta; 1999; 20(2-3):189-96. PubMed ID: 10195741
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
[TBL] [Abstract][Full Text] [Related]
15. Serum interferon level and (2'-5')oligoadenylate synthetase activity in lymphocytes during clinical interferon application.
Lodemann E; Nitsche EM; Lang MH; Gerein V; Altmeyer P; Holzmann H; Kornhuber B
J Interferon Res; 1985; 5(4):621-8. PubMed ID: 2418131
[TBL] [Abstract][Full Text] [Related]
16. High level activity of 2', 5'-oligoadenylate synthetase in dog serum.
Iwata A; Yamamoto A; Fujino M; Sato I; Hosokawa-Kanai T; Tuchiya K; Ishihama A; Sokawa Y
J Vet Med Sci; 2004 Jun; 66(6):721-4. PubMed ID: 15240951
[TBL] [Abstract][Full Text] [Related]
17. Native human IFN-alpha is a more potent suppressor of HDF response to profibrotic stimuli than recombinant human IFN-alpha.
Santak G; Santak M; Forcić D
J Interferon Cytokine Res; 2007 Jun; 27(6):481-90. PubMed ID: 17572012
[TBL] [Abstract][Full Text] [Related]
18. Novel sustained-release dosage forms of proteins using polyglycerol esters of fatty acids.
Yamagata Y; Iga K; Ogawa Y
J Control Release; 2000 Feb; 63(3):319-29. PubMed ID: 10601727
[TBL] [Abstract][Full Text] [Related]
19. [2',5'-oligoadenylate synthetase activity in peripheral blood mononuclear cells obtained from patients with chronic hepatitis B during interferon therapy].
Sugawara T
Hokkaido Igaku Zasshi; 1990 Sep; 65(5):439-54. PubMed ID: 2227795
[TBL] [Abstract][Full Text] [Related]
20. The woodchuck interferon-alpha system: Cloning, family description, and biologic activity.
Berraondo P; García-Navarro R; González-Aseguinolaza G; Vales A; Blanco-Urgoiti B; Larrea E; Riezu-Boj JI; Prieto J; Ruiz J
J Med Virol; 2002 Nov; 68(3):424-32. PubMed ID: 12226832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
